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Brown fat activation reduces
hypercholesterolaemia and protects from
atherosclerosis development
Jimmy F.P. Berbe´e1,2,*, Marie¨tte R. Boon1,2,*, P. Padmini S.J. Khedoe1,2,3,*, Alexander Bartelt4,5,*,y,
Christian Schlein4, Anna Worthmann4, Sander Kooijman1,2, Geerte Hoeke1,2, Isabel M. Mol1,2, Clara John4,
Caroline Jung6, Nadia Vazirpanah1,2, Linda P.J. Brouwers1,2, Philip L.S.M. Gordts7, Jeffrey D. Esko7,
Pieter S. Hiemstra3, Louis M. Havekes1,2,8,9, Ludger Scheja4, Joerg Heeren4,y & Patrick C.N. Rensen1,2,y
Brown adipose tissue (BAT) combusts high amounts of fatty acids, thereby lowering
plasma triglyceride levels and reducing obesity. However, the precise role of BAT in plasma
cholesterol metabolism and atherosclerosis development remains unclear. Here we show that
BAT activation by b3-adrenergic receptor stimulation protects from atherosclerosis in
hyperlipidemic APOE*3-Leiden.CETP mice, a well-established model for human-like lipoprotein
metabolism that unlike hyperlipidemic Apoe / and Ldlr/ mice expresses functional
apoE and LDLR. BAT activation increases energy expenditure and decreases plasma trigly-
ceride and cholesterol levels. Mechanistically, we demonstrate that BAT activation enhances
the selective uptake of fatty acids from triglyceride-rich lipoproteins into BAT, subsequently
accelerating the hepatic clearance of the cholesterol-enriched remnants. These effects
depend on a functional hepatic apoE-LDLR clearance pathway as BATactivation in Apoe /
and Ldlr/ mice does not attenuate hypercholesterolaemia and atherosclerosis.
We conclude that activation of BAT is a powerful therapeutic avenue to ameliorate hyper-
lipidaemia and protect from atherosclerosis.
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C
ardiovascular diseases are the leading cause of morbidity
and mortality in the Western world. Hyperlipidaemia,
and in particular hypercholesterolaemia, is a major risk
factor for the development of atherosclerosis, the main under-
lying cause of cardiovascular diseases. As current treatment
strategies of atherogenic hyperlipidaemia prevent only 30%
of all cardiovascular events1, novel treatment strategies are
highly warranted.
Brown adipose tissue (BAT) is a highly active metabolic tissue
that is present and active in adults2–7. Brown adipocytes not only
reside in BAT depots but also lie scattered in certain white
adipose tissue (WAT) depots. The development of these so-called
peripheral, inducible brown adipocytes or ‘beige/bright cells’ is
termed ‘browning’8,9. Both brown and beige adipocytes are
functionally thermogenic and characterized by a large number of
mitochondria and numerous small lipid droplets10. Physio-
logically, cold exposure activates BAT via stimulation of
noradrenalin release by sympathetic neurons, which
subsequently binds to b3-adrenergic receptor (b3-AR) on the
brown adipocyte membrane11. As the b3-AR is selectively found
on brown and white adipocytes, and WAT does not substantially
contribute to energy expenditure (EE), the cold-stimulated
activation of brown adipocytes inducing thermogenesis can be
pharmacologically mimicked by selective b3-AR agonists such as
CL316243, one the most selective b3-AR agonists available11,12.
However, cold exposure induces systemic hormonal changes and
ultimately leads to marked adipose tissue remodelling, including
proliferation and increased BAT mass. b3-AR agonists, in
contrast, along with inducing browning are only activating
existing BAT11. As in cold exposure shivering thermogenesis is
modulated and many other hormonal changes occur, b3-AR
agonists represent an excellent experimental tool to study the
effects of BAT activation selectively. Activation of the b3-AR on
brown adipocytes rapidly induces intracellular lipolysis of
triglycerides (TGs) from lipid droplets, resulting in release of
fatty acids (FAs) into the cytoplasm. FAs are directed towards
mitochondria where they either activate the uncoupling protein-1
(UCP1) in the inner membranes of mitochondria13 or undergo
oxidation. The intracellular TG stores of brown adipocytes are
rapidly replenished mainly by uptake of FA derived from lipolysis
of TG-rich lipoproteins (TRLs) in the plasma14.
We showed that activation of BAT in mice via cold
exposure15,16 or metformin treatment17 potently reduces
plasma TG levels and obesity. Therefore, activation of BAT is
now considered a promising new therapeutic avenue to combat
hypertriglyceridemia and obesity18,19. However, increased
lipolytic processing of plasma TRL naturally accelerates
formation of pro-atherogenic cholesterol-rich remnants as well,
which are usually cleared by the liver. Thus, Dong et al.20
described that BAT activation by cold exposure aggravates
hypercholesterolaemia and atherosclerosis development in
Apoe / and Ldlr / mice, which are the most widely used
atherosclerosis mouse models. Apolipoprotein E (ApoE) is an
apolipoprotein mediating the clearance of remnant lipoproteins
through interacting with hepatic lipoprotein receptors, including
the low-density lipoprotein receptor (LDLR)21. Although Apoe /
 mice predominantly display an accumulation of cholesterol-
enriched very-low-density lipoprotein (VLDL) remnants and
very low high-density lipoprotein (HDL) levels22,23, Ldlr /
mice are characterized by high levels of remnant lipoproteins and
LDL-cholesterol (LDL-C) without significant changes in HDL
levels24. It is likely to be that the enhanced clearance of plasma
TGs on BAT activation may require efficient clearance of
cholesterol-enriched lipoprotein remnants by the liver, a
pathway that is considered to be crucially dependent on a
functional apoE-LDLR axis21.
The APOE*3-Leiden.CETP (E3L.CETP) model is a well-
established model for hyperlipidaemia and atherosclerosis, which,
unlike Apoe / and Ldlr / mice, responds well to the lipid-
lowering and anti-atherogenic effects of statins25, fibrates26
and niacin27. E3L.CETP mice express a naturally occurring
mutant form of human apoE3 that slows down remnant
clearance, but does not completely abrogate the interaction with
the LDLR28. This results in attenuated hepatic remnant clearance
that is sufficient to induce hyperlipidaemia and atherosclerosis
when feeding a Western-type diet (WTD), but, importantly, the
hepatic remnant clearance route is still functional and can be
modulated. In addition, E3L.CETPmice are transgenic for human
cholesteryl ester transfer protein (CETP), which transfers
cholesteryl esters from HDL to (V)LDL particles and for which
rodents are naturally deficient. Hence, E3L.CETP mice are
considered to display a more human-like lipoprotein metabolism.
Here we investigate the effects of b3-AR-mediated BAT
activation12 on cholesterol metabolism and atherosclerosis
development in E3L.CETP mice. Using TRL-mimicking
particles, we show that the lipolytic conversion of TRLs by BAT
increases the hepatic clearance of cholesterol-enriched lipoprotein
remnants. This sequence of events results in a pronounced
reduction in plasma TG and cholesterol levels, and ultimately in a
marked attenuation of atherosclerosis development. In addition,
we show that Apoe / and Ldlr / mice do not respond to the
plasma cholesterol-lowering activity of BAT and are not protected
from atherosclerosis development, underlining the importance of
the apoE–LDLR axis for the anti-atherogenic activity of BAT.
Results
Activation of BAT augments FA combustion. We first assessed
the effect of BAT activation on EE and fat storage in female
E3L.CETP mice fed an atherogenic WTD for 10 weeks, while
being treated with the selective b3-AR agonist CL316243
(3 20 mg per mouse per week; subcutaneous) or vehicle (phos-
phate-buffered saline (PBS)). b3-AR agonism tended to reduce
body mass (up to  8%; Fig. 1a) and prevented total fat mass gain
(up to  81%; Fig. 1b), without affecting lean mass (Fig. 1c) and
cumulative food intake during the study (Fig. 1d). Accordingly, in
the b3-AR agonist-treated mice the weight of the individual WAT
pads was lower (ranging from  25% to  52%; Fig. 1e) and the
average size of the lipid droplet within white adipocytes was
smaller ( 48%; Fig. 1f,g).
The b3-AR-mediated prevention of body fat gain was probably
the consequence of increased adaptive thermogenesis, as total EE
was markedly increased on the day of treatment (þ 17%; Fig. 2a)
without differences in activity levels (Fig. 2b). The increase in EE
was confined to increased FA oxidation (þ 67%; Fig. 2c) rather
than carbohydrate oxidation (Fig. 2d) and, consequently, b3-AR
agonism reduced the respiratory exchange ratio ( 3.5%; Fig. 2e).
This increased EE was accompanied by a marked activation of
interscapular BAT (intBAT) as evidenced by reduced intracellular
lipid vacuole size in intBAT ( 87%; Fig. 3a,b) and reduced
weight of BAT pads (approximately  25%; Fig. 1e). UCP1
protein content per area of BAT was increased (þ 43%; Fig. 3c,d),
but not when expressed per total fat pad (Fig. 3e), suggesting
mainly the activation of existing BAT. In addition, b3-AR
agonism increased browning of WAT (Fig. 3f,g). These data
combined thus show that b3-AR agonism effectively activates
BAT, enhances EE and increases browning of WAT under
atherogenic conditions in E3L.CETP mice.
Activation of BAT increases hepatic VLDL remnant clearance.
We next investigated the effect of BAT activation on plasma lipid
levels in dyslipidemic E3L.CETP mice. BAT activation markedly
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reduced plasma TG levels throughout the treatment period
(approximately  54%; Fig. 4a), caused by a reduction in VLDL-
TG (Fig. 4b). Interestingly, BAT activation consistently reduced
plasma total cholesterol (TC) levels (approximately  23%;
Fig. 4c), also confined to a reduction in the (V)LDL fraction
(approximately  27%; Fig. 4d,e), without altering hepatic
expression of genes relevant for lipid and lipoprotein metabolism
(that is, Apob, CETP, Ldlr and Mttp; Supplementary Table 1).
This lipid-lowering effect of CL316243-mediated brown fat acti-
vation did not differ from cold-induced effects, as cold exposure
reduced hyperlipidaemia in E3L.CETP mice as well (Fig. 5a,b),
despite a marked increase in dietary cholesterol intake in the cold
(Fig. 5c).
We hypothesized that BAT activation reduces VLDL-TG as
well as (V)LDL-C, as a result of enhanced uptake of TG-derived
FA by BAT. Thus, the lipolytic processing of (V)LDL particles
may lead to the formation of smaller cholesterol-enriched
lipoprotein remnants, which are prone to be subsequently cleared
by the liver. Therefore, we studied the in vivo plasma clearance
and organ uptake of glycerol tri[3H]oleate (triolein, TO)- and
[14C]cholesteryl oleate (CO)-double-labelled VLDL-mimicking
particles (Fig. 6 and Supplementary Fig. 1)29 in E3L.CETP mice
that were treated for 8 days with CL316243, which is compared
with the long-term protocol (10 weeks as above) already sufficient
to stimulate BAT activity and browning.
In vehicle-treated mice, the plasma decay of [3H]TO (Fig. 6a)
was faster than that of [14C]CO (Fig. 6c; t½¼ 2.9±0.1 versus
4.7±0.5min; unpaired two-tailed Student’s t-test, Po0.01),
indicating that lipolytic processing and FA uptake precedes the
clearance of core remnants. The uptake of [3H]TO-derived activity
by the various BAT depots was much higher than by other
metabolically active tissues (Fig. 6b). The uptake of 3H-activity by
BAT depots (Fig. 6b) was much larger than that of 14C-activity
(Fig. 6d; average ratio 3H/14C¼ ‘lipolysis index’¼ 11.1±0.9),
indicating selective uptake of [3H]TO-derived [3H]oleate rather
than uptake of whole particles. Instead, the delipidated remnants
were mainly taken up by the liver (Fig. 6b,d and Supplementary
Fig. 1b; lipolysis index¼ 0.22±0.01).
b3-AR agonism markedly accelerated the plasma clearance of
[3H]TO (t½¼ 1.5±0.1 versus 2.9±0.1min; unpaired two-tailed
Student’s t-test, Po0.001; Fig. 6a) and [14C]CO (t½¼ 3.3±0.3
versus 4.7±0.5min; Fig. 6c). The accelerated clearance of
[3H]TO was explained by a pronounced increased uptake of
[3H]oleate by the various BAT depots (2–3 fold; Fig. 6b and
Supplementary Fig. 1a), in accordance with increased BAT
activity. The relative increase of [3H]TO uptake into BAT is
paralleled by [14C]CO uptake, indicating that activation of BAT
via b3-AR agonism increases both FA and holoparticle uptake
pathways to a similar extent. Interestingly, although the specific
uptake by the WAT depots was stillB15-fold lower as compared
with the BAT depots, b3-AR agonism also increased the uptake of
[3H]oleate by these WAT depots (2- to 3-fold), possibly reflecting
the activity of beige adipocytes within WAT. Concomitantly, BAT
activation increased the uptake of [14C]CO by the liver, byB25%
(Fig. 6d and Supplementary Fig. 1b), indicating accelerated
hepatic clearance of core remnants. The remnants that were
generated by BAT activation and subsequently taken up by the
liver were depleted from TG and more enriched in cholesterol as
compared with remnants in vehicle-treated mice as indicated by
an B30% reduction in lipolysis index (0.15±0.01 versus
0.22±0.01; unpaired two-tailed Student’s, t-test Po0.01; calcu-
lated from Fig. 6b,d).
Interestingly, additional univariate regression analyses showed
that the uptake of TG-derived FA (3H activity) by the various
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BAT depots predicted the uptake of the cholesterol-enriched
remnants (14C activity) by the liver (Fig. 6e–g). This lipid-
lowering effect of b3-AR agonism did not depend on CETP, as
CL316243 also reduced plasma lipid levels in E3L mice without
CETP (Fig. 7). Hence, BAT-mediated lipolytic processing of
VLDL promotes the clearance of the corresponding cholesterol-
rich remnants by the liver.
Activation of BAT reduces atherosclerosis development. Next,
we studied whether the decreased (V)LDL levels were accom-
panied by reduced atherosclerosis development. To this end, we
determined atherosclerotic lesion area as well as severity and
composition of the lesions in the root of the aortic arch after 10
weeks of BAT activation. Indeed, sustained BAT activation by
b3-AR agonism markedly reduced atherosclerotic lesion area
throughout the aortic root (Fig. 8a,b), resulting in 43% lower
mean atherosclerotic lesion area (Fig. 8c). BAT activation clearly
reduced the severity of the lesions, as indicated by more mild
lesions (that is, type I–III; þ 75%) and less severe lesions (that is,
type IV–V;  38%; Fig. 8d) without significantly affecting
atherosclerotic lesion composition (that is, collagen, vascular
smooth muscle cell and macrophage content of the lesions;
Fig. 8e–g) or the lesion stability index (that is, ratio collagen/
macrophage area; Fig. 8h).
To evaluate the contribution of TG versus TC lowering to the
reduction in atherosclerosis, univariate regression analyses were
performed. To linearize data for analysis, the atherosclerotic
lesion area was square root (SQRT) transformed27 and plotted
against the TG and TC exposure (that is, area under the curve of
plasma lipid for the complete treatment period). We found that
the SQRT of the lesion area did not correlate with plasma TG
exposure (b¼ 0.028; R2¼ 0.086; P¼ 0.10; Fig. 8i) but correlated
with plasma TC exposure (b¼ 0.054; R2¼ 0.333; Po0.001;
Fig. 8j). Additional univariate regression analyses showed that
the (V)LDL-C exposure specifically predicts the SQRT of the
lesion area (b¼ 0.055; R2¼ 0.358; Po0.001; Fig. 8k). Taken
together, these analyses reveal that a reduction in plasma
(V)LDL-C is the main contributor to the anti-atherogenic effect
of b3-AR-mediated activation of BAT.
Anti-atherogenic effect depends on hepatic remnant clearance.
As we observed increased hepatic uptake of lipoprotein remnants
after CL316243-induced BAT activation (Fig. 6d), we evaluated
the role of the apoE–LDLR axis, the main hepatic route
for clearance of TRL remnants21. Cold adaptation20 and
CL316243 treatment (data not shown) increased food intake in
both Apoe / and Ldlr / mice. Therefore, to match dietary
cholesterol intake, we studied the effect of b3-AR-mediated BAT
activation in WTD-pair-fed Apoe / mice and Ldlr / mice.
Similar as in E3L.CETP mice, activation of BAT reduced body
weight, WAT pad size and plasma TG levels (Fig. 9a and
Supplementary Fig. 2a–c). However, activation of BAT did
neither reduce plasma TC and (V)LDL-C levels (Fig. 9b
and Supplementary Fig. 2d), change hepatic gene expression
(Supplementary Table 1), nor did it reduce atherosclerosis
development (Fig. 9c,d) in Apoe / mice. As expected,
the SQRT of the lesion area did not correlate with either total
plasma TG exposure or plasma TC exposure during the
study (Fig. 9e,f).
As the LDLR is the main hepatic clearance receptor for apoE-
containing lipoprotein remnants21, we next investigated the role
of the LDLR for the (V)LDL-C-reducing effect of BAT activation.
Similar as in E3L.CETP and Apoe / mice, activation of BAT
reduced body weight, WAT pad size and plasma TG levels in
WTD-pair-fed Ldlr / mice (Fig. 9g and Supplementary
Fig. 3a–c). However, activation of BAT in Ldlr / mice did
neither reduce plasma TC and (V)LDL-C levels (Fig. 9h and
Supplementary Fig. 3d), change messenger RNA levels of selected
hepatic genes (Supplementary Table 1), nor reduce
atherosclerosis development (Fig. 9i,j), nor did the SQRT of the
lesion area correlate with the total plasma TG and TC exposure
during the study (Fig. 9k,l). Taken together, these findings
demonstrate that activation of BAT reduces plasma (V)LDL-C
and subsequently reduces atherosclerosis development through
enhanced LDLR-mediated hepatic clearance of apoE-containing
lipoprotein remnants.
Discussion
Since its rediscovery in human adults in the last decade2,4–7,30,
BAT has been considered a promising therapeutic target for
obesity and associated metabolic disorders. The anti-obesity
potential of BAT has been irrefutably proven in murine
studies18,19,31 and shown in human studies4,30,32,33. However,
in light of the study by Dong et al.20, the effect of BAT activation
on cholesterol metabolism and atherosclerosis development
remained controversial to date. Here we present evidence that,
in principle, BAT activation is beneficial and not deleterious for
plasma cholesterol metabolism and atherosclerosis development.
Using E3L.CETP and E3L mice, we demonstrate that
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BAT-mediated local lipolysis of TG-rich lipoproteins stimulated
hepatic clearance of lipoprotein remnants via a pathway involving
the apoE–LDLR pathway. As a result, BAT activation reduced
atherosclerotic lesion size and severity in E3L.CETP mice but not
in mice lacking either apoE or LDLR.
Our study indicates that the ability of the liver to clear apoE-
enriched lipoprotein remnants via the LDLR is a prerequisite for
the anti-atherogenic potential of BAT activation. According to
this view, it is not surprising that Dong et al.20 recently observed
that BAT activation by cold exposure in Apoe / and Ldlr /
mice actually increased plasma (V)LDL-C levels and
atherosclerosis. Likewise, in these hyperlipidemic mouse models
prolonged BAT activation results in lipoprotein remnant levels in
plasma exceeding the hepatic clearance capacity. In fact, Dong
et al.20 did show that activation of BAT by cold in
normolipidemic wild-type C57Bl/6 mice actually decreased
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plasma TC and (V)LDL-C levels, which is in full accordance with
a functional hepatic apoE–LDLR clearance route of lipoprotein
remnants in wild-type mice. It is also reasonable that in mice
lacking UCP1 in addition to apoE or LDLR, the formation of
remnants is impaired, thereby apparently paradoxically
protecting these mice from atherosclerosis20. As we observe
that both CL316243 treatment (Fig. 4) and cold exposure
(Fig. 5a,b) reduce hyperlipidaemia in E3L.CETP mice our
results provide proof for the concept that in principle BAT
activation has beneficial effects on plasma lipids.
In this study, we used TRL-mimicking particles as models
for TRLs. We previously showed that these particles rapidly
acquire an array of exchangeable apolipoproteins from serum,
including apoE, apoCs, apoAIV, apoAI, apoAII and apoD29,34,
and that the hepatic uptake of their core remnants is mediated
by apoE34. In fact, the in-vivo kinetics of [3H]cholesteryl
oleate-labelled TRL-mimicking particles34 are very similar to
those of [3H]vitamin A-labelled native chylomicrons35, with
similar clearance rate from plasma (t½ B2min) and uptake by
the liver (B65%–75% after 30min). Lactoferrin reduced the
uptake by the liver of both TRL-mimicking particles and
chylomicrons by B75%35 and liver cell distribution studies
confirmed that hepatocytes accounted for B75% of the total
uptake by the liver35. Taken together, it is likely to be that the
present findings with TRL-mimicking particles can be translated
to endogenous TLRs.
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Our work sets the foundation for future studies that investigate
the anti-atherogenic potential of BAT in humans, especially since
a recent study demonstrated that b3-AR agonism activates BAT
and increases EE in humans36. As the discovery that functional
BAT is present and active in human adults was made only
in the last decade2,4–7,30, recent studies have focused on the
physiological relevance of BAT for humans. The concept of BAT
being involved in energy metabolism and being a target for
obesity was appreciated some decades ago based on experimental
studies in rodents37,38. More recently, its role in human energy
metabolism and obesity development became apparent as well,
from observations that BAT activity inversely correlates with
obesity39, and that cold acclimation recruits BAT40 and lowers fat
mass33. In addition, South Asians, who have a high susceptibility
to metabolic disorders, have decreased EE associated with
decreased BAT volume and activity compared with white
Caucasians, although it should be noted that body composition
is different between these ethnicities41. Importantly, BAT
activation by means of cold acclimation also improved
cholesterol metabolism in human patients with
hypercholesterolaemia42, underscoring the potential of BAT
activation as a potential anti-atherogenic treatment in humans.
In conclusion, our data demonstrate that activation of BAT
lowers atherogenic lipoprotein levels and protects against
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atherosclerosis development. Moreover, we show the importance
of a functional hepatic apoE–LDLR clearance pathway, rendering
Apoe / or Ldlr / mice inappropriate models for studying
the beneficial effects of BAT modulation on plasma cholesterol
metabolism and atherosclerosis development. We propose that
BAT activation, resulting in accelerated generation of lipoprotein
remnants, should preferentially be combined with strategies that
increase hepatic LDLR expression, including statins and/or
proprotein convertase subtilisin/kexin type 9 blockers, thus fully
unravelling the therapeutic potential of BAT for atherosclerosis
prevention and treatment.
Methods
Mice and animal procedures. Female E3L were cross-bred with mice expressing
human CETP under control of its natural flanking regions, to generate hetero-
zygous E3L.CETP mice25. Female E3L.CETP and E3L mice were 10–12 weeks of
age and individually housed under standard conditions with a 12-h light–dark
cycle, free access to food and water, and 22 C room temperature. Mice were fed a
WTD (HopeFarms, Woerden, The Netherlands) supplemented with 0.1%
cholesterol and treated with the b3-AR agonist CL316243 (Tocris Bioscience
Bristol, UK; 3 20mg per mouse per week; subcutaneous) or vehicle (PBS) for 10
weeks. Food intake and body weight, as well as total body fat and lean mass, were
monitored by EchoMRI-100 (EchoMRI, Houston, Texas) during the studies.
Male Apoe / and Ldlr / mice (Jackson Laboratory, Bar Harbor, ME) were
individually housed and fed a WTD supplemented with 0.2% cholesterol with
or without CL316243 (0.001% w/w). As CL316243 treatment of Apoe / and
Ldlr / mice increased food intake, these mice were pair-fed to their respective
controls after onset of effect. All animal experiments were approved by the
Ethics Committee on Animal Care and Experimentation of the Leiden University
Medical Center or The Animal Welfare Committee of University Medical Center
Hamburg-Eppendorf.
Indirect calorimetry. Indirect calorimetry was performed in fully automatic
metabolic cages (LabMaster System, TSE Systems, Bad Homburg, Germany) during
the ninth week of treatment. After 1 day of acclimatization, O2 consumption, CO2
production and caloric intake were measured for 3 consecutive days42. Total EE was
estimated from the VO2 and resting energy requirement. Carbohydrate oxidation
was calculated using the formula ((4.585*VCO2) (3.226*VO2))*4, in which the 4
represents the conversion from mass per time unit to kcal per time unit43. Similarly,
fat oxidation was calculated using the formula ((1.695*VO2) (1.701*VCO))*9.
Values were normalized to lean mass. Physical activity was monitored using infrared
sensor frames. The first 12 h directly after injection with CL316243 or vehicle (‘Day
of treatment’) were analysed and compared with the same 12-h period 24 h later
(‘Day after treatment’).
Cold exposure. Mice were individually housed with ad libitum access to WTD
and water during exposure to 4 C in a cold room with a 12-h light–dark cycle.
After 7 days of cold exposure 4 h-fasted plasma lipids were determined as
described below.
In-vivo plasma decay and organ uptake of VLDL-like particles. VLDL-like TG-
rich emulsion particles (80 nm) labelled with glycerol tri[3H]oleate (TO) and
[14C]CO were prepared and characterized as described previously29. Briefly,
[3H]TO (100 mCi) and [14C]CO (10 mCi) tracers were added to a mixture of TO
(70mg), egg yolk phosphatidylcholine (22.7mg), lysophosphatidylcholine (2.3mg),
CO (3.0mg) and cholesterol (2.0mg). Particles were prepared from this mixture at
54 C using a Soniprep 150 (MSE Scientific Instruments, UK) at 10 mm output. The
emulsion was fractionated by consecutive density gradient ultracentrifugation steps
in a Beckman SW 40 Ti rotor. After centrifugation (27min, 20,000 r.p.m., 20 C)
the top fraction containing chylomicron-like particles with an average size of
150 nm was discarded. After a subsequent centrifugation step (27min,
40,000 r.p.m., 20 C) VLDL-like particles with an average size of 80 nm were
isolated, stored at 4 C under argon and used within 5 days.
After 8 days of treatment with the b3-AR agonist CL316243 (20 mg per mouse
per day) mice were fasted for 4 h and injected (t¼ 0) via the tail vein with the
emulsion particles (1.0mg TG per mouse in 200ml PBS). Blood samples were taken
from the tail vein at 2, 5, 10 and 15min after injection, to determine the plasma
decay of [3H]TO and [14C]CO. Plasma volumes were calculated as 0.04706 body
weight (g) as determined from 125I-labelled BSA clearance studies as described44.
After 15min, mice were killed by cervical dislocation and perfused with ice-cold
heparin solution (0.1% v/v in PBS) via the heart, to remove blood from the organs
and tissues. Subsequently, organs and tissues were isolated, dissolved overnight at
56 C in Tissue Solubilizer (Amersham Biosciences, Rosendaal, The Netherlands)
and quantified for 3H and 14C activity. Uptake of [3H]TO- and [14C]CO-derived
radioactivity by the organs and tissues was expressed per gram wet tissue weight or
calculated as dose per organ after correction for organ weight.
Plasma parameters and lipoprotein profiles. Blood was collected from the tail
vein of 4-h fasted mice into EDTA- (E3L.CETP and E3L mice) or lithium-heparin-
coated tubes (Apoe / and Ldlr / mice). Tubes were placed on ice, centrifuged
and plasma was isolated and assayed for TG and TC by using commercially
available enzymatic kits from Roche Diagnostics (Mannheim, Germany). Plasma
(V)LDL-C levels were calculated by extraction of HDL-C from TC levels. HDL-C
levels were determined by precipitating apoB-containing lipoproteins from plasma
by addition of 20% polyethylene glycol in 200mM glycine buffer with pH 10 and
TC was measured in the supernatant as described above. The distribution of TG
and cholesterol over lipoproteins was determined in pooled plasma by fast-per-
formance liquid chromatography on a Superose 6 column (GE Healthcare,
Piscataway, NJ).
Hepatic gene expression analysis. Total RNA was extracted from snap-frozen
livers using Tripure RNA isolation reagent (Roche, Mijdrecht, The Netherlands),
according to the manufacturer’s instructions. Complementary DNA for quantita-
tive reverse transcriptase–PCR was produced by reverse transcription of total RNA
using Moloney Murine Leukemia Virus Reverse Transcriptase (Promega, Leiden,
The Netherlands). mRNA expression was normalized to b2-microglobulin and 36b4
mRNA content and expressed as fold change compared with control mice. The
primer sequences used are listed in Supplementary Table 2.
Necropsy and histology of BAT and WAT. At the end of the study, mice
were anaesthetized by intraperitoneal injection of acepromazine (6.25mg kg 1;
Alfasan, Woerden, The Netherlands), midazolam (0.25mg kg 1; Roche,
Mijdrecht, The Netherlands) and fentanyl (0.31mg kg 1; Janssen-Cilag, Tilburg,
The Netherlands), bled and killed by cervical dislocation or transcardial blood
withdrawal. The blood circulation was perfused with ice-cold heparin solution
(0.1% v/v in PBS), and organs and tissues were weighed and collected for further
analyses. Epididymal WAT and intBAT were removed and preserved in phos-
phate-buffered 4% formaldehyde and embedded in paraffin. Haematoxylin–eosin
staining was performed using standard protocols. Intracellular lipid droplet size
in WAT and percentage of lipid-droplet-positive area in BAT were quantified using
Image J software (version 1.47).
For UCP1 staining, 5-mm sections were deparafinnized in xylene, rehydrated in
ethanol and treated with 3% H2O2 (Sigma-Aldrich, Zwijndrecht, The Netherlands)
in absolute methanol for 30min, to block endogenous peroxidase activity.
Sections were immersed in citrate buffer (10mM, pH 6) and boiled for 10min.
Slides were blocked with 1.3% normal goat serum (in PBS) and incubated
overnight at 4 C with rabbit monoclonal anti-UCP1 antibody (Abcam, Cambridge,
UK; 1:400 in 1.3% normal goat serum). Subsequently, sections were incubated
for 60min with biotinylated goat a-rabbit secondary antibody (Vector Labs,
Burlingame, CA) diluted in 1.3% normal goat serum. Immunostaining was
amplified using Vector Laboratories Elite ABC kit (Vector Labs) and the
immunoperoxidase complex was visualized with Nova Red (Vector Labs).
Counterstaining was performed with Mayer’s haematoxylin (1:4). Expression of
UCP1 was quantified using Image J software (version 1.47) and expressed per area
and per total fat pad.
Atherosclerosis quantification. Hearts were collected and fixated in phosphate-
buffered 4% formaldehyde, embedded in paraffin and cross-sectioned (5 mm)
perpendicular to the axis of the aorta throughout the aortic root area, starting
from the appearance of open aortic valve leaflets. Per mouse, four sections with
50-mm intervals were used for atherosclerosis measurements. Sections were stained
with haematoxylin–phloxine–saffron for histological analysis. For Apoe /
and Ldlr / mice, paraffin-embedded hearts were cross-sectioned (10-mm) and
stained with modified Van Gieson stain. Per mouse, three consecutive cross-sec-
tions per 100-mm intervals were used for atherosclerosis measurements, starting at
the appearance of open aortic valve leaflets. Lesions were categorized for lesion
severity according to the guidelines of the American Heart Association adapted
for mice45. Various types of lesions were discerned: mild lesions (types 1–3) and
severe lesions (types 4–5). Lesion area was determined using Image J Software
(version 1.47). Quantification of smooth muscle cell actin was performed
using antibody M0851 (Dako, Carpinteria, CA) and DAKO envision anti-mouse
(Vector Laboratories Inc., Burlingame, CA). Rat monoclonal anti-MAC-3 antibody
(BD Pharmingen, San Diego, CA) and Vector Impress anti-rat (Vector
Laboratories Inc.) were used to quantify macrophage area. Immunostainings were
amplified using Vector Laboratories Elite ABC kit (Vector Laboratories Inc.)
and the immunoperoxidase complex was visualized with Nova Red (Vector
Laboratories Inc.). Sirius red (Chroma, Stuttgart, Germany) was used to stain for
collagen. The stability index was calculated by dividing the collagen by the
macrophage area.
Statistical analyses. Statistical analyses between genotypes were assessed using
the unpaired two-tailed Student’s t-test. Univariate regression analyses were per-
formed to test for significant correlations between uptake of 14C activity in the liver
and 3H activity in intBAT, and between atherosclerotic lesion area and plasma lipid
exposures during the study. Multiple regression analysis was performed to predict
the contribution of plasma TG and TC exposures during the study to the
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atherosclerotic lesion area. The SQRT of the lesion area was taken to linearize the
relationship with the plasma lipid exposures. Data are presented as mean±s.e.m.,
unless indicated otherwise. Differences at a probability level (P) of 0.05 were
considered statistically significant. SPSS 20.0 for Windows (SPSS, Chicago, IL) was
used for statistical analyses.
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